Frontiers in Anti-Cancer Drug Discovery

Volume 7


Atta-ur-Rahman, FRS , M. Iqbal Choudhary

DOI: 10.2174/97816810825161160701
eISBN: 978-1-68108-251-6, 2016
ISBN: 978-1-68108-252-3
ISSN: 2451-8395 (Print)
ISSN: 1879-6656 (Online)

Indexed in: EMBASE, EBSCO, Ulrich's Periodicals Directory.

"Frontiers in Anti-Cancer Drug Discovery" is an eBook series devoted to publish...[view complete introduction]
US $
Buy Personal eBook
Order Library eBook
Order Printed Copy
Order PDF + Printed Copy (Special Offer)

*(Excluding Mailing and Handling)

🔒Secure Checkout Personal information is secured with SSL technology
Download Flyer

Cyclin E and its Potential Use for Liver Cancer Prognosis and Therapy

- Pp. 228-242 (15)

Nikki P. Lee


Liver cancer is an aggressive malignancy developed in the liver. Hepatocellular carcinoma (HCC) is the predominant form of liver cancer worldwide. The prognosis of HCC patients remains poor even with the evolving development on technologies for disease diagnosis, prognosis and treatment. New methods to improve the management of HCC patients should be implemented. Cell cycle deregulation is one key mechanism leading to HCC. Cyclin E is a cell cycle molecule regulating G1 to S phase transition of the cell cycle. The prominent cell cycle regulating function of cyclin E has signified its involvement in HCC when its activity is deregulated. This chapter summarizes the current research on cyclin E in HCC and with a special focus on its underlying, well-studied downstream mechanism involving retinoblastoma-E2F transcriptional factor network. Lastly, research on the potential use of cyclin E for HCC prognosis and treatment is also highlighted and discussed.

Purchase Chapter  Book Details


Webmaster Contact: Copyright © 2019 Bentham Science